The Chairman of the company has started a blog for keeping all posted about the activities. The post mentions that he will provide more details about the pivotal US clinical trials in subsequent posts and also explain the $1 billion opportunity PLCSF is trying to pursue. It will be interesting to see the details mentioned in the future posts. So far the company has been able to build a good portfolio of patents around RenalGuard. It has numerous US patents and one patent from Europe, Canada and Japan covering both core methodology and other aspects of RenalGuard therapy. The product has been appreciated at recent conferences, but the real jump in sales will come only if it gets accepted in US. Success in the trials hold the key for that, and the company needs to move as fast as possible on that front. Further, the margins may perhaps be better if the product is sold in US. At present Europe is the main market, and the sales had increased last year, and in the last quarter on a yoy basis. The product is known to have good potential, but it may take some time for that to translate into higher sales and net profits. In any case, the current valuations factor that. The first post explains the indication or the problem which the product is addressing, namely Acute Kidney Injury (AKI). It explains how the contrast dye used in diagnostic or other procedures can cause damage to the kidney, and how RenalGuard can help address the issue. RenaGuard is being sold outside US already, and thousands of patients have been treated so far. The blog will help remain updated about the activities of the company. The company has also put up an Executive Video on its website where the Chairman reviews the Company's strategy and vision for RenalGuard.
